<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Res Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Res Cardiol</journal-id><journal-title-group><journal-title>Clinical Research in Cardiology</journal-title></journal-title-group><issn pub-type="ppub">1861-0684</issn><issn pub-type="epub">1861-0692</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7252421</article-id><article-id pub-id-type="publisher-id">1656</article-id><article-id pub-id-type="doi">10.1007/s00392-020-01656-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation </article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>B&#x000f6;hm</surname><given-names>Michael</given-names></name><address><email>michael.boehm@uks.eu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Frey</surname><given-names>Norbert</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Giannitsis</surname><given-names>Evangelos</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sliwa</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zeiher</surname><given-names>Andreas M.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411937.9</institution-id><institution>Klinik f&#x000fc;r Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, </institution><institution>Universit&#x000e4;tsklinikum des Saarlandes, Saarland University, </institution></institution-wrap>Kirrberger Str. 1, 66421 Homburg, Saar Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412468.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0646 2097</institution-id><institution>Klinik f&#x000fc;r Innere Medizin III, </institution><institution>Universit&#x000e4;tsklinikum Schleswig-Holstein, </institution></institution-wrap>Kiel, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.5253.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0328 4908</institution-id><institution>Innere Medizin III, Medizinische Klinik, </institution><institution>Universit&#x000e4;tsklinikum Heidelberg, </institution></institution-wrap>Heidelberg, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.7836.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1151</institution-id><institution>Faculty of Health Sciences, Hatter Institute for Cardiovascular Research in Africa, </institution><institution>University of Cape Town, </institution></institution-wrap>Cape Town, South Africa </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.7839.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9721</institution-id><institution>Department of Medicine&#x02013;Cardiology,, </institution><institution>J.W. Goethe University, </institution></institution-wrap>Frankfurt, Germany </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>5</month><year>2020</year></pub-date><fpage>1</fpage><lpage>14</lpage><history><date date-type="received"><day>17</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>24</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Coronavirus diseases 2019 (COVID-19) has become a worldwide pandemic affecting people at high risk and particularly at advanced age, cardiovascular and pulmonary disease. As cardiovascular patients are at high risk but also have dyspnea and fatigue as leading symptoms, prevention, diagnostics and treatment in these patients are important to provide adequate care for those with or without COVID-19 but most importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with acute respiratory distress (ARDS) is challenging as patients with elevated myocardial markers such as troponin are at enhanced high risk for fatal outcomes. As angiotensin-converting enzyme 2 (ACE2) is regarded as the viral receptor for cell entry and as the Coronavirus is downregulating this enzyme, which provides cardiovascular and pulmonary protection, there is ongoing discussions on whether treatment with cardiovascular drugs, which upregulate the viral receptor ACE2 should be modified. As most of the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease and heart failure, which imposes a high risk on these patients, cardiovascular therapy should not be modified or even withdrawn. As cardiac injury is a common feature of COVID-19 associated ARDS and is linked with poor outcomes, swift diagnostic management and specialist care of cardiovascular patients in the area of COVID-19 is of particular importance and deserves special attention.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>CORONA</kwd><kwd>COVID-19</kwd><kwd>Heart failure</kwd><kwd>Hypertension</kwd><kwd>Cardiovascular risk</kwd><kwd>Myocardial injury</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>COVID-19 and cardiovascular care</title><p id="Par2">After the first cases of respiratory illness were reported in December 2019, a novel coronavirus, designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified to cause the so-called coronavirus disease (COVID-19), which meanwhile has become a worldwide pandemic [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In general, three distinct phases characterize progression of COVID-19: an initial infection phase followed by a respiratory distress phase and finally culminating in a severe hyperinflammation state with more than 80% of SARS-CoV-2 infections showing only mild or even absent symptoms [<xref ref-type="bibr" rid="CR3">3</xref>]. The characteristics from the COVID-19 outbreak reported from China [<xref ref-type="bibr" rid="CR3">3</xref>] provided important lessons with respect to cardiovascular involvements both as a primary target as well as a comorbidity. The infection phase marks virus infiltration and proliferation of the epithelium and lung parenchyma accompanied by mild symptoms and monocyte / macrophage activation as the initial immune response. The ensuing inflammatory processes like vasodilation, endothelial leakiness and leukocyte extravasation lead to pulmonary distress with pulmonary damage, fluid extravasation and hypoxemia, which in turn augments cardiovascular stress. Finally, further amplification of the host inflammatory response will essentially culminate in systemic inflammation up to eliciting a cytokine storm [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par3">Importantly, the cardiovascular system emerges as both a primary target as well as the most important secondary co-morbidity factor during all three of the COVID-19 progression phases (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). There is accumulating evidence that the heart itself might be a direct target for viral infection with SARS-CoV-2 [<xref ref-type="bibr" rid="CR5">5</xref>]. Previous studies examining the cardiovascular effects of viral respiratory infections during influenza epidemics revealed a profound up to sixfold increased incidence ratio for acute myocardial infarction within 7&#x000a0;days of infection, in part due to the heightened prothrombotic activity leading to intracoronary thrombotic events [<xref ref-type="bibr" rid="CR6">6</xref>]. Hypotension and tachycardia will further imbalance the metabolic demand of a diseased heart. Exaggerated systemic inflammation with profoundly increased circulating levels of prototypical inflammatory markers such as IL-6, IL-2, TNFalpha; MCP-1 or CRP are well established to contribute to cardiac injury irrespective of the presence of hypoxemia. Indeed, some of these biomarkers were shown to be associated with high mortality in retrospective clinical series of COVID-19 patients hospitalized in China [<xref ref-type="bibr" rid="CR7">7</xref>], indicating potential serious bystander effects on other organs, including the heart. In support of such collateral damage to the heart, increased inflammatory markers do correlate with electrocardiographic abnormalities and biomarkers of cardiac injury [<xref ref-type="bibr" rid="CR8">8</xref>]. Finally, elevation of cardiac biomarkers documenting cardiac involvement is not only a prominent feature in COVID-19, but is also associated with a profoundly worse clinical outcome [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Myocardial damage and heart failure contributed to almost 40% of deaths in a critically ill cohort hospitalized in Wuhan [<xref ref-type="bibr" rid="CR11">11</xref>]. Cox regression analyses revealed that the mortality risk associated with acute cardiac damage was significantly higher than age, chronic pulmonary disease or prior history of cardiovascular disease [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Thus, both direct and indirect mechanisms of cardiovascular injury most likely play a pivotal role for the deleterious consequences of SARS-CoV-2 infection in addition to the severe acute respiratory distress syndrome (ARDS).<fig id="Fig1"><label>Fig. 1</label><caption><p>Summary of consequences of SARS-Cov2 infection on the cardiovascular system summarizing primary targets (left) and secondary comorbidities (right)</p></caption><graphic xlink:href="392_2020_1656_Fig1_HTML" id="MO1"/></fig></p><p id="Par4">Last, patients with underlying cardiovascular disease are more likely to be infected with SARS-CoV-2, are more likely to develop severe symptoms, if infected with SARS-CoV-2, and may also be more vulnerable to adverse cardiotoxic effects of treatment with antiviral drugs. A most recent analysis from the LEOSS registry [<xref ref-type="bibr" rid="CR12">12</xref>] displaying the prevalence of co-morbidities in COVID-19 patients in Germany disclosed that in all classes of disease severity more than 50% of the patients suffered from cardiovascular co-morbidity, which was by far the most prominent co-morbidity associated with COVID-19 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Distribution of comorbidities in different intensities of COVID-19 infections</p></caption><graphic xlink:href="392_2020_1656_Fig2_HTML" id="MO2"/></fig></p><p id="Par5">Taken together, cardiovascular involvement is both highly prevalent and of significant prognostic importance in COVID-19. Therefore, it is not only important to fully involve cardiologists for managing cardiovascular complications in severe cases of COVID-19, but also to pay particular attention to cardiovascular protection of patients at risk to develop COVID-19. It will be essential to allocate sufficient resources for cardiovascular diagnostic and therapeutic procedures, even at times when the health care systems are globally overwhelmed and hospitals are guided by measures to contain and treat this infectious disease. We need to advice patients that cardiovascular emergencies like STEMI, decompensated heart failure or life-threatening arrhythmias need immediate attention and treatment and emergency calls should not be delayed out of fear for being admitted to a hospital with the potential to acquire COVID-19. We do need to set-up emergency treatment strategies for non-COVID-19 patients in-hospital and assure protection of these patients from SARS-CoV-2-infected patients. Additionally, we need to make sure to that hospital staff and health care workers in general are adequately protected and diagnostic and interventional procedures in COVID-19 patients are guided by clinical necessity. Fortunately, all major cardiovascular professional societies are meanwhile in the process of publishing guidance for various aspects of cardiovascular care in COVID-19 patients, including how and in whom to perform diagnostic and therapeutic interventions. Some of these guidance publications will be referenced to in the following chapters of this article. This will without any doubt lead to greater awareness of the immediate cardiovascular implications of this infectious disease.</p><p id="Par6">Nevertheless, we should not stop here. Hospitalization for pneumonia was previously shown to be associated with a significantly increased risk of cardiovascular disease up to 10&#x000a0;years of follow-up [<xref ref-type="bibr" rid="CR13">13</xref>]. It is very likely that SARS-CoV-2 infections with respiratory impairment will also lead to similar long-term adverse events. We need to monitor COVID-19 patients with acutely elevated markers of cardiac damage with respect to long-term consequences on cardiac function, including definite proof of SARS-CoV-2-induced myocarditis by myocardial biopsy. Likewise, it will be important to assess potential long-term cardiotoxic effects of antiviral therapy. Thus, cardiovascular care during the COVID-19 pandemic should already implement strategies to capture longer-term implications by prolonged clinical follow-up.</p></sec><sec id="Sec2"><title>COVID and low-middle income countries</title><p id="Par7">COVID-19 has spread to almost all countries of the world. Unexplained is the different impact of the disease in different countries. There has been a slow increase in infections in Africa and South-East Asia with a surprisingly low fatality rate. 14th April 2020 South Africa had 2272 infections with 27 deaths despite a detailed surveillance system (<ext-link ext-link-type="uri" xlink:href="http://www.coronavirus.jhu.edu">www.coronavirus.jhu.edu</ext-link> accessed 14th April 2020). It is currently unknown why there has been so far a slower than expected rise in cases and case mortality in low-to-middle income countries. The population demographics and underlying co-morbidities are vastly different in those countries. The mean age of many low-to-middle income countries is more than 2 decades lower than in higher income countries. For example in Uganda the life expectancy at birth for males and females is 60 and 65&#x000a0;years (<ext-link ext-link-type="uri" xlink:href="http://www.who.org">www.who.org</ext-link>), 48.5% of the population is in the age range of 0&#x02013;14&#x000a0;years old with just 2% of the population being older than 60&#x000a0;years. This age pyramid influences the current Uganda cardiovascular health challenges which does include hypertension and coronary artery disease, mainly in urban areas, but rheumatic heart disease (RHD) and heart failure due to cardiomyopathies remain enormous challenges. Most of the patients do not have access to balloon valvotomy or surgery [<xref ref-type="bibr" rid="CR14">14</xref>]. Untreated symptomatic patients with rheumatic heart disease have a mortality rate of 20% per annum leaving very few patients being able to live beyond their 40&#x000a0;years of age [<xref ref-type="bibr" rid="CR15">15</xref>]. However, there are other factors which might have an impact. The country-by-country difference in COVID-19 morbidity and mortality could possibly be explained by national policies on Bacillus Calmette Guerin (BCG) vaccination. BCG is a live attenuated strain derived from an isolate of myocobacterium bovis used widely across the world as a vaccine for tuberculosis, with many low-to-middle income countries but also some high-income countries such as Japan having a universal BCG vaccination policy in newborns. BCG vaccinations have been shown to produce non-specific immune effects leading to an improved response against other non-myocardial pathogens. Another possible protective mechanism could be the high number of people living with HIV/AIDS on anti-retroviral therapy. South Africa has a population of 57 million with&#x02009;&#x0003e;&#x02009;12% being HIV-infected. SA has the world&#x02019;s largest antiretroviral therapy (ART) program, subsidized by the government and provided free-of-charge. Only time will tell if low-to middle income countries will &#x02018;catch up&#x02019; on the pandemic in 2020 and 2021 or remain relatively spared [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par8">The World Heart Federation has published a briefing on prevention: Coronavirus Disease 2019 in low-income countries [<xref ref-type="bibr" rid="CR17">17</xref>]. This includes six easy rules to reduce the risk of corona virus transmission. From staying at home and avoiding large gathering to a total shut down of a country had so far the biggest impact in a lower number of infections and early case detection.</p></sec><sec id="Sec3"><title>Hypertension</title><sec id="Sec4"><title>The role of the renin&#x02013;angiotensin&#x02013;aldosterone system in COVID-19</title><p id="Par9">The renin&#x02013;angiotensin&#x02013;aldosterone system (RAAS) regulates blood pressure and is also involved in cardiovascular endorgan damage like myocardial hypertrophy, interstitial myocardial fibrosis, atherosclerosis and plaque rupture in acute coronary syndromes. Therefore, blockers of the RAAS are recommended for the use in hypertension to prevent cardiovascular events and heart failure [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. The protease renin cleaves angiotensin to angiotensinogen I (Ang 1&#x02013;10), which then is processed to angiotensin II (Ang 1&#x02013;8) by the angiotensin-converting enzyme (ACE) [<xref ref-type="bibr" rid="CR20">20</xref>]. Angiotensin II stimulates AT1-receptors, which results in adverse cardiovascular effects like vasoconstriction, cell proliferation and hypertrophy [<xref ref-type="bibr" rid="CR21">21</xref>]. In contrast, the AT2-receptor mediates vasodilation, anti-proliferative actions and apoptosis and has been suggested to be involved in anti-proliferative effects upon binding of angiotensin II [<xref ref-type="bibr" rid="CR22">22</xref>]. Angiotensin II [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>] is cleaved by the angiotensin-converting enzyme 2 (ACE2) into angiotensin (<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR23"> 23</xref>), which exerts directly a stimulation of the so called &#x0201c;MAS-receptor&#x0201d;, mediating vasodilation, anti-proliferative effects and anti-inflammatory responses [<xref ref-type="bibr" rid="CR24">24</xref>]. It is now well established that the CORONA virus family binds via its spike protein to ACE2 [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] with well characterized binding residues [<xref ref-type="bibr" rid="CR27">27</xref>]. After proteolytic modification of ACE2 [<xref ref-type="bibr" rid="CR28">28</xref>] and the coronavirus spike protein [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>] by a membrane-bound proteinase (ADAM17), the virus is internalized by clathrin-coated pits and, after trypsin cleavage, viral RNA is released into this cellular cytoplasm causing SARS infection [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. ACE2 is degraded and shedfrom the cell membrane into the circulation after cleavage by ADAM17 [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. As a result, there is a downregulation of ACE2 by the CORONA virus itself [<xref ref-type="bibr" rid="CR31">31</xref>]. The role of ACE2 in CORONA virus infection is scrutinized by the fact that several animals cannot be infected by the CORONA virus when there is a knockout of ACE2, which renders them resistant to infection [<xref ref-type="bibr" rid="CR32">32</xref>]. The role of ACE2 is not specific for the CORONA virus as ACE2 is also used by the respiratory syncytial (RS) virus and some types of influenza viruses [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par10">ACE2 can also be regulated in several cardio-pulmonary disease conditions like COPD, pulmonary hypertension, asthma and after viral infections with influenza H1N1, H5N1, H7N9 as well as in sepsis [<xref ref-type="bibr" rid="CR35">35</xref>]. ACE2, potentially by degrading maladaptive angiotensin II and stimulating anti-inflammatory responses through the MAS receptor [<xref ref-type="bibr" rid="CR24">24</xref>], has been shown to improve lung injury after viral infections of clinical injuries [<xref ref-type="bibr" rid="CR36">36</xref>]. Furthermore, ARDS is not prominent after RS virus infections, when the ACE2 is knocked out [<xref ref-type="bibr" rid="CR33">33</xref>]. In addition, recombinant human ACE2 has been tested in a pilot study in human ARDS and has been shown to reduce circulating interleukin-6 concentrations accompanied by increases of Ang 1&#x02013;7 and reductions of angiotensin II [<xref ref-type="bibr" rid="CR37">37</xref>]. Therefore, ACE2 might be crucial for the entry of CORONA viruses into the cells and, hence, infectivity [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]; however, it might also mediate beneficial effects on pulmonary complications after infection [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. The fact that the major risk factor for adverse outcomes in COVID-19 is age, and ACE2 is downregulated in the aging population, argues in favor of its role in poor outcome of that risk group [<xref ref-type="bibr" rid="CR35">35</xref>]. Furthermore, drugs like chloroquine and indometazine [<xref ref-type="bibr" rid="CR35">35</xref>] as well as ACE inhibitors and ARBs [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>] have been shown to upregulate ACE2 in the human heart and in the systemic as well as pulmonary vasculature [<xref ref-type="bibr" rid="CR40">40</xref>] with association to outcomes in heart failure [<xref ref-type="bibr" rid="CR41">41</xref>], atrial fibrillation [<xref ref-type="bibr" rid="CR42">42</xref>] and pulmonary hypertension [<xref ref-type="bibr" rid="CR43">43</xref>]. These findings highlight the complex interaction of COVID-19 and ACE2 inhibition. We would thus raise the hypothesis that pathophysiological conditions or drugs enhancing ACE2 expression might lead to greater infectivity, but, at the same time potentially reduce mortality due to lung complications (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Hypothetical scheme for the interaction of the CORONA virus and angiotensin converting enzyme-2 (ACE2). The CORONA virus binding with its spike protein to ACE2, which is processed by the proteinase ADAM17 leading to the internalization of the CORONA virus and ACE2 into the cell where the viral genome is released. The internalization as well as the shedding of ACE2 from the cell surface and its release into the circulation reduces membrane-bound ACE2. Furthermore, ACE2 is reduced by pathological conditions like pulmonary fibrosis, asthma, COPD, pulmonary hypertension, smoking and old age [<xref ref-type="bibr" rid="CR17">17</xref>]. On the contrary, membrane-bound ACE2-concentrations are higher following treatment with ACE-inhibitors, AT1-blockers and potentially ibuprofen, and ACE2 is more abundantly expressed in childhood and at young age. As ACE2 forms more Ang 1&#x02013;7 from angiotension-II to stimulate the MAS-receptor mediating anti-proliferative, anti-inflammatory action, hypothetically enhanced ACE2-expression might cause more infection by acting as a receptor for viral cell entry and protect from pulmonary complications. In conditions where is downregulation of ACE2, less infection might occur, but severity of COVID-19-related ARDS can be more severe. This hypothesis fits with the higher likelihood of pulmonary complications in certain disease conditions and in aging. Notably, these data are derived from experimental and observational data, but not from controlled clinical studies and need to be scrutinized in clinical conditions</p></caption><graphic xlink:href="392_2020_1656_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec5"><title>Is hypertension a risk factor for COVID-19?</title><p id="Par11">Arterial hypertension is the most prevalent risk factor in cardiovascular disease, in particular in China [<xref ref-type="bibr" rid="CR44">44</xref>]. In several early trials of COVID-19 populations, hypertension is the most prevalent cardiovascular risk factor and comorbidity is amounting to approximately 30&#x02013;40% in the overall population of diseased individuals in China [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] and Italy [<xref ref-type="bibr" rid="CR47">47</xref>]. In those patients, who have complications or even died, hypertension is more prevalent as was diabetes, coronary artery disease, chronic obstructive lung disease or malignancies [<xref ref-type="bibr" rid="CR9">9</xref>]. As hypertension is the comorbidity with the highest prevalence in deceased patients, it has been claimed to be a risk factor for COVID-19. However, this would only be the case, if there is a deviation from the overall prevalence of hypertension in the Chinese population. In China, the prevalence of hypertension is high. By comparing Chinese populations age-matched to those in reports on COVID-19 (approximately 55&#x02013;74&#x000a0;years), it becomes clear that the overall prevalence in hypertension is 44% with a further increase in populations at higher age [<xref ref-type="bibr" rid="CR48">48</xref>]. Therefore, the prevalence of the comorbidity hypertension in COVID-19 patients is lower and does not exceed the overall prevalence in the relevant populations in China. Therefore, there is no evidence that hypertension increases the likelihood to suffer from COVID-19. Cardiovascular risk factors and comorbidities are elevated in patients who have fatal outcomes after COVID-19 [<xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, all cardiovascular comorbidities in concert add to myocardial injury, which has been shown to be closely associated with death as measured from cardiac troponin levels [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par12">The next question arises of whether cardiac treatments and treatments with the renin-angiotensin system inhibitors (RASi), in particular ACE-inhibitors (ACE-I) or angiotensin receptor blockers (ARBs) are associated with a differential outcome in COVID-19. The Guidelines for the Management of Hypertension of the European Society of Cardiology [<xref ref-type="bibr" rid="CR18">18</xref>], but also Chinese guidelines [<xref ref-type="bibr" rid="CR49">49</xref>] and Guidelines of the American College of Cardiology (ACC) and American Heart Association (AHA) [<xref ref-type="bibr" rid="CR19">19</xref>] recommend ACE and ARBs for the treatment of hypertension as these drugs have been shown to be effective in secondary prevention, heart failure and protection against adverse renal outcomes. In Germany, as in other countries in Europe, the prescription rate of ACE and ARBs are higher than all prescribed daily doses of other anti-hypertensive drugs combined [<xref ref-type="bibr" rid="CR50">50</xref>]. However, adequate blood pressure control in China in the age group, where COVID-19 is most prevalent, was only 34.9&#x02013;35.6% [<xref ref-type="bibr" rid="CR51">51</xref>] according to the 2010 Chinese guidelines [<xref ref-type="bibr" rid="CR49">49</xref>] and 15,2&#x02013;16,0% according to the 2017 ACC/AHA guidelines [<xref ref-type="bibr" rid="CR19">19</xref>]. In particular, the frequency of ACE-inhibitor treatment is particularly low in an Asian population (in particular in females), because the ACE-induced coughing is more prevalent than in other populations [<xref ref-type="bibr" rid="CR51">51</xref>]. Therefore, the low density of treatment with RASi does not argue in favor of a significant role of these drugs in the likelihood of COVID-19. The upregulation of ACE2 by RASi does not allow to argue in favor or against the use of RAS-inhibitors in hypertension as recently expressed in various short communications and letters causing a lot of discussion and media attention [<xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>]. Although, a large body of evidence has been generated in cell models, animal models and observational studies, further data are necessary to scrutinize the definite role of ACE2 in infection frequency and causation of pulmonary complications after CORONA infections. At this moment, there is thus no compelling evidentiary background to change RASi therapy for hypertension or other cardiovascular conditions.</p></sec></sec><sec id="Sec6"><title>COVID-19 and myocardial injury</title><p id="Par13">The cardiac manifestations of SARS-CoV-2 infection include acute myocardial injury, heart failure, myocarditis, and ventricular tachyarrhythmias [<xref ref-type="bibr" rid="CR59">59</xref>]. Along with ARDS, acute myocardial injury was identified as an important independent predictor of outcomes, associated with a 3.4-fold higher risk of death [<xref ref-type="bibr" rid="CR9">9</xref>]. In a cohort of 416 hospitalized patients, the prevalence of cardiac injury-based on the presence of elevated hs-cTnI values above the 99th percentile of a healthy reference population&#x02014;was 19.7%, and the risk of death increased with the magnitude of myocardial injury, expressed as multiples of the reference value of hs-TnI [<xref ref-type="bibr" rid="CR9">9</xref>]. Unequivocally, other cohorts investigating the prevalence and prognostic implications of myocardial injury during the COVID-19 outbreak in Wuhan, China, reported very similar rates of acute myocardial injury ranging between 7.2% [<xref ref-type="bibr" rid="CR45">45</xref>], 12% [<xref ref-type="bibr" rid="CR10">10</xref>], 17% [<xref ref-type="bibr" rid="CR7">7</xref>] and 27.8% [<xref ref-type="bibr" rid="CR8">8</xref>] at presentation based on elevations of hs-cTn above the ULN. In a report on 138 patients hospitalized with COVID-19 [<xref ref-type="bibr" rid="CR45">45</xref>], patients who received care in the intensive care unit were more likely to have cardiac injury than non-ICU patients (22.2% vs 2%). &#x000b4;Consistently, in another study on 41 admitted hospital patients with laboratory-confirmed COVID-19 [<xref ref-type="bibr" rid="CR10">10</xref>], the proportion of patients requiring care on the intensive care unit (ICU) was significantly higher among patients with evidence of acute myocardial injury (31% vs 4%). Several studies demonstrate an association between acute myocardial injury and mortality [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. In a study on 187 patients with COVID-19 that evaluated the role of hs-cTnT relative to the presence of cardiovascular disease [<xref ref-type="bibr" rid="CR8">8</xref>], mortality rates were highest among patients with elevated hs-cTnT above ULN and history of cardiovascular disease and lowest among those with normal hs-cTn, irrespective the presence or absence of CV disease [<xref ref-type="bibr" rid="CR8">8</xref>]. In a survey on 416 hospitalized patients in Wuhan [<xref ref-type="bibr" rid="CR9">9</xref>], only 26.2% of patients (22 of 82 patients) received an ECG, particularly during periods of elevation of cardiac biomarkers while imaging tests such as echocardiography were not reported. Consistently other reports [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR60">60</xref>] did not report on rates of ECG or other imaging tests, except lung CT, at all. Hence, the limited diagnostic workup and selection bias precludes any speculations on the etiology of hs-cTnI elevation.</p><p id="Par14">Discordant to the recommendations of the 4th version of the universal myocardial infarction (MI) definition (UDMI) [<xref ref-type="bibr" rid="CR61">61</xref>], the investigators of the Wuhan studies used a different definition for acute myocardial injury and did not differentiate acute from chronic myocardial injury by a concentration change (&#x0201c;rise and/or fall&#x0201d;) of hs-cTnI. Acute myocardial injury was rather defined as blood levels of high sensitivity troponin T or I above the 99th percentile upper limit of normal (upper limit of normal (ULN)&#x02009;&#x0003e;&#x02009;28&#x000a0;ng/L), or new abnormalities shown on electrocardiography and echocardiography [<xref ref-type="bibr" rid="CR10">10</xref>]. The investigators did not report on rates and subtypes of acute myocardial infarction based on criteria of the 4th version of the UDMI [<xref ref-type="bibr" rid="CR61">61</xref>]. Interestingly, hs-cTn values increased during serial monitoring in patients with a fatal outcome whereas persistently low values were observed among survivors allowing to speculate whether monitoring of hs-cTn might be useful even in the absence of a suspected acute coronary syndrome [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par15">Overall, the presence of myocardial injury in ED populations is not uncommon, occurring in as many as 20% of consecutive patients presenting with chest pain, dyspnea, or less specific symptoms [<xref ref-type="bibr" rid="CR62">62</xref>]. However, only a fraction of elevations was ultimately attributed to a type 1 or type 2 MI and the majority of cases were unrelated to myocardial ischemia, often multifactorial, or the exact reason remained unsettled [<xref ref-type="bibr" rid="CR61">61</xref>]. In stable or asymptomatic cardiovascular or ischemic heart disease, cardiac troponin elevation may be explained by the presence of underlying structural heart disease, stable CAD, and chronic kidney disease [<xref ref-type="bibr" rid="CR63">63</xref>]. Accordingly, in Western countries, the presence of hs-cTn above the 99th percentile ULN has been reported in as many as 20% of asymptomatic patients with or without cardiovascular disease presenting for routine outpatient visits [<xref ref-type="bibr" rid="CR63">63</xref>], and across different sub-specialities in patients hospitalized for reasons other than an acute coronary syndrome [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Regardless the underlying reason or acuity of clinical presentation, the presence of myocardial injury as indicated by hs-cTn above the 99th percentile is uniformly associated with adverse long-term outcomes and patients with elevated hs-cTn at baseline have a higher risk to die acutely during the precipitating event due to their cardiovascular morbidity [<xref ref-type="bibr" rid="CR63">63</xref>]. Accordingly, the data from the pandemia in Wuhan, confirm current knowledge but do not provide fundamental new information to our interpretation of troponin elevations.</p><sec id="Sec7"><title>Acute myocardial injury related to COVID-19</title><p id="Par16">Based on findings from Corona and Influenza infections in the past, it has been speculated that acute myocardial injury might be triggered or facilitated in COVID-19 infection [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. A previous study on the incidence of myocardial infarction after the outbreak of Influenza infections in Ontario reported a sixfold higher incidence ratio of AMI within 6&#x000a0;days after a positive Influenza test as compared to a negative test during the same time frame [<xref ref-type="bibr" rid="CR66">66</xref>]. It was hypothesized that an exaggerated inflammatory response mediated by viral infection with Influenza A or B, respiratory syncytial virus (RSV) or other virus had the potential to trigger acute plaque rupture. In addition, anecdotal evidence from sporadic case reports raised the suspicion of acute myocarditis, although a direct SARS-CoV-2 infiltration of the heart has not been confirmed in the absence of histological confirmation by endocardial biopsy, or by detection of viral genome in myocardial tissue, yet [<xref ref-type="bibr" rid="CR67">67</xref>]. Previously, a decline in left ventricular ejection fraction (LV-EF) and a highly prevalent reversible, subclinical diastolic left ventricular impairment that was reported in acute SARS-CoV-2 infection and was attributed to the cytokine storm syndrome that is characterized by an uncontrolled and dysfunctional immune response [<xref ref-type="bibr" rid="CR68">68</xref>]. Finally, cardiotoxic effects of antiviral therapies have been reported [<xref ref-type="bibr" rid="CR69">69</xref>].</p></sec><sec id="Sec8"><title>Acute myocardial injury not directly related to COVID-19</title><p id="Par17">Acute myocardial injury may occur independently from COVID-19 and may manifest as type 1 myocardial infarction (STEMI or NSTEMI), type 2 MI in the absence of plaque rupture or intracoronary thrombus, or as an acute myocardial injury independent of myocardial ischemia (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Cases of acute MI on autopsy during hospitalization for COVID-19 have been reported [<xref ref-type="bibr" rid="CR7">7</xref>] but a systematic evaluation is lacking. Given the paucity of data on the exact prevalence and reasons for an acute myocardial injury during COVID-19, our interpretation of hs-cTn elevations has to be discussed on knowledge previously derived from other acute critical conditions, foremost severe infections causing sepsis or septic shock [<xref ref-type="bibr" rid="CR70">70</xref>]. In an investigation on hs-cTnT in setting of severe infection, median concentrations of hs-cTnT were found to increase from 14.4&#x000a0;ng/L in sepsis to 52.6&#x000a0;ng/L in severe sepsis and 64.1&#x000a0;ng/L in septic shock [<xref ref-type="bibr" rid="CR70">70</xref>]. Likewise, the prevalence of hs-cTnT&#x02009;&#x0003e;&#x02009;ULN increased from 51.6% in sepsis to 80.4% % in septic shock [<xref ref-type="bibr" rid="CR70">70</xref>]. Very similar to COVID-19, mild elevations of hs-cTnT were associated with a high mortality rate at 30&#x000a0;days [<xref ref-type="bibr" rid="CR71">71</xref>]. However, the risk associated with myocardial injury at baseline persisted over 5&#x000a0;years after the index event suggesting a major prognostic role of pre-existing structural heart disease on long-term outcomes. Similar to SARS-CoV-2 infection, an impairment of right and left ventricular function on echocardiography was common during other severe infections and there was a clear association between myocardial injury, cardiac overload or hemodynamic stress as indicated by natriuretic peptides and inflammatory response [<xref ref-type="bibr" rid="CR72">72</xref>]. Significant elevations of hs-cTn have been demonstrated following rapid atrial pacing, irrespective the presence of inducible myocardial ischemia [<xref ref-type="bibr" rid="CR73">73</xref>]. In an experimental human model that utilized the trans-cardiac production of lactate for objective evidence of myocardial ischemia, hs-cTnT increased in the absence of CAD and lactate suggesting that tachycardia itself is capable to induce an acute myocardial injury. Likewise, administration of catecholamines was found to release hs-cTnT in healthy volunteers [<xref ref-type="bibr" rid="CR74">74</xref>]. Other mechanisms that have been related to the release of cTn include respiratory failure due to severe hypoxemia, sepsis, acute kidney failure, hypertension or hypotension, bradycardia, fever, anemia and many other causes [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].<fig id="Fig4"><label>Fig. 4</label><caption><p>Manifestations of myocardial injury and potential pathomechanisms of release of cardiac troponin during COVID-19 infection</p></caption><graphic xlink:href="392_2020_1656_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec9"><title>Practical considerations for patients presenting with suspected or confirmed COVID-19 infection and suspected Type I Myocardial Infarction (T1MI)</title><p id="Par18">Acute MI with or without COVID-19 represents a life-threatening condition that requires adjunctive medical therapies such as potent antiplatelet drugs and monitoring to anticipate complications. However, the enhanced infectious potency in humans [<xref ref-type="bibr" rid="CR75">75</xref>] mandates a fundamental risk assessment to carefully weigh the relative advantages against disadvantages of treating cardiovascular disease while preventing the risk of SARS-CoV-2 transmission.</p><p id="Par19">In patients with suspected ACS without ST-segment elevation, or in the absence of hemodynamic or rhythm instability and when COVID-19 cannot be ruled-out due to suspicious clinical presentation, the personal recommendation of the author is to obtain nasopharyngeal swabs for real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay and, if available, to perform a CT lung scan while waiting for the PCR result. COVID-19-associated pneumonia provides a typical picture that is characterized by bilateral lung infiltrates, glass ground opacities, consolidation, reticular pattern and the so-called crazy paving pattern [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. The sensitivity of CT is reported as high as 97&#x02013;99% and is superior that of RT-PCR [<xref ref-type="bibr" rid="CR76">76</xref>]. The CT scan could ideally be performed as a multi-detector CT angiography providing additional information on coronary anatomy and on the presence of pulmonary embolism since elevations of D-Dimer are not uncommon [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR60">60</xref>] and values exceeding the two&#x02013;sixfold of the ULN are associated with high mortality [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>].</p><p id="Par20">Regarding the measurement of cardiac biomarkers, the American College of Cardiology (ACC) has released statements against the liberal use of troponin in COVID-19 [<xref ref-type="bibr" rid="CR78">78</xref>]. Given the frequency and non-specific nature of abnormal troponin results among patients with COVID-19, clinicians are advised to measure cardiac troponin only if acute myocardial infarction is suspected on clinical grounds [<xref ref-type="bibr" rid="CR78">78</xref>]. The European Society of Cardiology (ESC) expands these recommendations by restricting the measurement of cardiac troponin T/I concentrations to patients with suspected Type 1 MI, because this infarct type is more likely to benefit from adjunctive antiplatelet therapies and early revascularization therapies (personal communication, paper under revision).</p><p id="Par21">Moreover, in order to reduce the length of stay in an ED, and to dedicate monitoring capacities for other critically diseased patients, accelerated rapid rule-out and/or rule-in of MI seem to be particularly helpful [<xref ref-type="bibr" rid="CR79">79</xref>]. Real world evidence suggests that patient disposition may be completed within 2&#x02013;3&#x000a0;h without an increase of adverse outcomes compared to standard protocols [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. Use of echocardiography or coronary angiography should be restricted to those patients in whom these procedures would be expected to meaningfully affect outcomes [<xref ref-type="bibr" rid="CR78">78</xref>]. Timing of invasive coronary angiography depends on individual estimation of anticipated risk of death, heart failure or other infarct-related complications. Factors that are supposed to favor an immediate or early coronary angiography under full protection of medical staff include STEMI, high risk non-ST segment elevation MI as suggested by either unstable hemodynamics, dynamic ST segment changes, rhythm instability, or a very high clinical score as recommended in 2015 ESC guidelines [<xref ref-type="bibr" rid="CR79">79</xref>]. Cardiac troponin values should be interpreted as continuous variables since risk of death and benefits from an early invasive strategy incline with increasing values [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. It is unclear whether the benefit of revascularization outweighs the potential disadvantages of contamination of medical staff in patients with small-to-intermediate elevations of hs-cTn, or whether a yet unsettled, more refined risk stratification is required to identify those patients who are likely to benefit most [<xref ref-type="bibr" rid="CR83">83</xref>]. Hence, patients with NSTEMI at lower risk should be managed according to local expertise and capability to deliver echocardiography and invasive procedures effectively to the patient without exposing the medical staff to an increased risk of contamination [<xref ref-type="bibr" rid="CR84">84</xref>&#x02013;<xref ref-type="bibr" rid="CR87">87</xref>].</p></sec></sec><sec id="Sec10"><title>Heart failure and COVID-19</title><sec id="Sec11"><title>Is heart failure a risk factor for COVID-19?</title><p id="Par22">It has long been known that patients with chronic heart failure (CHF) are at increased risk for adverse consequences of seasonal influenza [<xref ref-type="bibr" rid="CR88">88</xref>] and other causes of pneumonia [<xref ref-type="bibr" rid="CR89">89</xref>]. Conversely, infections and in particular pneumonia are frequent triggers of heart failure exacerbations [<xref ref-type="bibr" rid="CR90">90</xref>]. Of note, influenza vaccination decreases mortality in CHF patients and the beneficial effects of repetitive influenza vaccinations may even exceed those of guideline-directed pharmacotherapy [<xref ref-type="bibr" rid="CR91">91</xref>]. Severe coronavirus infections such as with SARS-CoV-2 have been shown to result in a more severe course of disease in patients with preexisting cardiovascular disease, including heart failure [<xref ref-type="bibr" rid="CR92">92</xref>]. Thus it is not surprising that COVID-19 is associated with higher morbidity and mortality in patients with cardiovascular comorbidities [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. Yet, likely due to the lower prevalence of (known) CHF in China, there is still limited specific information on patients with preexisting heart failure. Nevertheless, some early reports [<xref ref-type="bibr" rid="CR9">9</xref>] indicate that COVID-19 associated myocardial injury (s. below) is more frequent in patients with heart failure and other cardiovascular comorbidities.</p></sec></sec><sec id="Sec12"><title>Myocardial injury in COVID-19</title><p id="Par23">Up to 30% of hospitalized COVID-19 patients [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] reveal elevated troponin levels as a marker of myocardial injury. While the precise mechanisms for myocardial necrosis in the context of SARS-CoV-2 is unknown (s. below), troponin elevations are potent predictors of an adverse outcome. Shi et al. [<xref ref-type="bibr" rid="CR9">9</xref>] reported that increased troponin levels were associated with a higher likelihood for mechanical ventilation, development of ARDS and acute kidney failure. Remarkably, 42 of 82 patients with myocardial injury died (51.2%), whereas only 15 of 334 troponin negative patients had a lethal outcome. Similarly, Guo et al. [<xref ref-type="bibr" rid="CR8">8</xref>] showed that an elevated troponin predicted ARDS, ventricular arrhythmias such as VTs VFib and death. Interestingly, a continuous increase in NT-proBNP and troponin T and was observed in those patients that ultimately died, while survivors revealed constant levels. Of note, troponin elevations appear to be more predictive of prognosis than the presence of comorbidities as patients with higher troponin levels but without preexisting cardiovascular or pulmonary disease have a significantly worse prognosis than troponin negative patients with cardiovascular comorbidities (Guo). It seems likely that myocardial injury is not only a marker of an adverse outcome but also a direct cause. This notion is supported by data that show that COVID-19 non-survivors frequently develop heart failure (52%) and shock (70%) [<xref ref-type="bibr" rid="CR7">7</xref>]. Similarly, Ruan et al. [<xref ref-type="bibr" rid="CR11">11</xref>] reported that in 68 patients who died of COVID-19, myocardial dysfunction was the sole or a contributing factor for death in 40% of the cases.</p><sec id="Sec13"><title>Potential mechanisms for myocardial injury in COVID-19</title><p id="Par24">An obvious reason for an elevated troponin level could be acute coronary syndrome that obviously may also occur in COVID-19 patients, and which is likely to be underdiagnosed due to reluctance for invasive management (s. above). However, the high proportion of typically rather moderately increased high sensitive troponin levels in hospitalized COVID-19 patients renders other explanations more likely, including acute myocarditis due to SARS-CoV-2 or myocardial damage due to proinflammatory cytokines (&#x0201c;cytokine storm&#x0201d;). ACE2 as a potential receptor for Coronavirus infection (s. above) is highly expressed in cardiomyocytes and in vascular pericytes [<xref ref-type="bibr" rid="CR94">94</xref>]. Thus, it seems plausible that SARS-CoV-2 may directly cause viral myocarditis with associated cell death and subsequent myocardial injury as measured by increased troponin levels. Indeed, the first still anecdotal autopsy and endomyocardial biopsy reports describe evidence for an acute lymphocytic myocarditis [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. However, the SARS-CoV-2 genome could not be detected in the myocardium of several of these early cases, indicating that other mechanisms of myocardial injury must be involved, at least in a subset of patients with myocardial injury.</p></sec><sec id="Sec14"><title>Hyperinflammatory myocardial injury (&#x0201c;cytokine storm&#x0201d;)</title><p id="Par25">Another attractive hypothesis how myocardial injury in the context of COVID-19 may be explained is a hyperinflammatory state where dysregulated cytokines mediate cardiomyocyte stress and ultimately cell death. Such a &#x0201c;cytokine storm&#x0201d; is a well-known [<xref ref-type="bibr" rid="CR97">97</xref>] while underappreciated syndrome complicating sepsis in up to 4% of cases [<xref ref-type="bibr" rid="CR98">98</xref>]. Its clinical characteristics include multiorgan failure associated with persistent fever and lymphopenia as well as high levels of ferritin and several cytokines such as interleukin-6. For example, elevated interleukin-6 (IL-6) levels closely correlate with mortality in sepsis and IL-6 has been shown to directly impair contractile function of cardiomyocytes [<xref ref-type="bibr" rid="CR99">99</xref>]. Similarly, lymphopenia and excessively elevated ferritin and interleukin-6 levels have been demonstrated in severe cases of COVID-19 which also revealed myocardial injury with increased high sensitive troponin.</p></sec><sec id="Sec15"><title>Specific treatment of the &#x0201c;cytokine storm&#x0201d; and heart failure in COVID-19?</title><p id="Par26">Multiple clinical trials are underway which test antiviral agents potentially effective against SARS-CoV-2, such as remdesivir and several antivirals previously shown to be effective eg in HIV infections (reviewed in [<xref ref-type="bibr" rid="CR100">100</xref>]. As myocardial injury is associated with a dramatically worsened outcome in COVID-19, the question arises whether therapy should also be specifically aimed at the prevention of myocardial damage and/or hyperinflammation. Indeed, the limited experience with inhibition of the cytokine storm by immunosuppression points towards this possibility. For example, interleukin-1 blockade by anakinra has been shown to reduce mortality in sepsis with hyperinflammation [<xref ref-type="bibr" rid="CR101">101</xref>]. Similarly, tocilizumab, an interleukin-6 receptor blocking antibody, shows early promise in COVID-19: In a non-randomized trial involving 20 patients, CRP levels and oxygen levels were almost normalized within a few days [<xref ref-type="bibr" rid="CR102">102</xref>]. Other promising targets include JAK inhibitors such as baricitinib [<xref ref-type="bibr" rid="CR103">103</xref>], immunoglobulins, or fingolimod. Finally, it has even been proposed that angiotensin receptors blockers eg. losartan may not only be not harmful (s. above) in COVID-19, but in fact beneficial as they upregulate ACE2, which could ameriolate tissue damage due to SARS-CoV-2 [<xref ref-type="bibr" rid="CR104">104</xref>]. Data on removal of cytokines by adsorbent polymer beads (&#x0201c;Cytosorb&#x0201d;) are sparse.</p></sec></sec><sec id="Sec16"><title>Perspectives</title><p id="Par27">Coronavirus disease 2019 (COVID-19) is a pandemic after an outbreak of pneumonia caused by the novel coronavirus occurred in Wuhan, China. Meanwhile it has spread throughout the world and is associated with mortality rates between 1 to about 5%. Cardiovascular disease is an important risk indicator for adverse outcomes and COVID-19 might affect the cardiovascular system directly. Angiotensin-converting enzyme 2 (ACE2) has been shown to be a coreceptor for viral entry downregulating ACE2 with cardiovascular consequences. Cardiovascular disease with dyspnea as a prime symptom like in heart failure, myocardial ischemia or hypertensive emergency is an important differential diagnosis, should not be ignored in COVID-19 and needs to be recognized as an important indicator of poor outcome. While there is no evidence for changing cardiovascular therapy, a complete cardiovascular workup is necessary in COVID-19 patients and, in particular, in patients with cardio-respiratory symptoms and even in acute respiratory distress syndrome. In turn, cardiopulmonary symptoms should not distract physicians from an unbiased work-up of cardiovascular conditions as these patients could suffer from life-threatening cardiovascular conditions in the absence of COVID-19. Healthcare providers in high, middle and low income countries need to be aware of the importance of cardiovascular disease in patients with SARS and COVID-19 infections by providing optimal cardiovascular care.</p></sec></body><back><fn-group><fn><p>For the German Cardiac Society: Michael B&#x000f6;hm, Norbert Frey, Evangelos Giannitsis and Andreas M. Zeiher. For the World Heart Federation: Michael B&#x000f6;hm and Karen Sliwa.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cucinotta</surname><given-names>D</given-names></name><name><surname>Vanelli</surname><given-names>M</given-names></name></person-group><article-title>WHO declares COVID-19 a pandemic</article-title><source>Acta Biomed</source><year>2020</year><volume>91</volume><fpage>157</fpage><lpage>160</lpage><?supplied-pmid 32191675?><pub-id pub-id-type="pmid">32191675</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinelli</surname><given-names>A</given-names></name><name><surname>Pellino</surname><given-names>G</given-names></name></person-group><article-title>COVID-19 pandemic: perspectives on an unfolding crisis</article-title><source>Br J Surg</source><year>2020</year><pub-id pub-id-type="doi">10.1002/bjs.11627</pub-id><?supplied-pmid 32363596?><pub-id pub-id-type="pmid">32363596</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>McGoogan</surname><given-names>JM</given-names></name></person-group><article-title>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72&#x0202f;314 cases from the chinese center for disease control and prevention</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id><?supplied-pmid 32275295?><pub-id pub-id-type="pmid">32275295</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology</article-title><source>Semin Immunopathol</source><year>2017</year><volume>39</volume><fpage>529</fpage><lpage>539</lpage><?supplied-pmid 28466096?><pub-id pub-id-type="pmid">28466096</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>JH</given-names></name><name><surname>Liu</surname><given-names>YX</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>FX</given-names></name><name><surname>Wu</surname><given-names>WB</given-names></name><name><surname>Li</surname><given-names>JX</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>CF</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Xie</surname><given-names>XJ</given-names></name><name><surname>Feng</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>First case of COVID-19 complicated with fulminant myocarditis: a case report and insights</article-title><source>Infection</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s15010-020-01424-5</pub-id><?supplied-pmid 32277408?><pub-id pub-id-type="pmid">32277408</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>JC</given-names></name><name><surname>Schwartz</surname><given-names>KL</given-names></name><name><surname>Campitelli</surname><given-names>MA</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Crowcroft</surname><given-names>NS</given-names></name><name><surname>Karnauchow</surname><given-names>T</given-names></name><name><surname>Katz</surname><given-names>K</given-names></name><name><surname>Ko</surname><given-names>DT</given-names></name><name><surname>McGeer</surname><given-names>AJ</given-names></name><name><surname>McNally</surname><given-names>D</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Rosella</surname><given-names>LC</given-names></name><name><surname>Simor</surname><given-names>A</given-names></name><name><surname>Smieja</surname><given-names>M</given-names></name><name><surname>Zahariadis</surname><given-names>G</given-names></name><name><surname>Gubbay</surname><given-names>JB</given-names></name></person-group><article-title>Acute myocardial infarction after laboratory-confirmed influenza infection</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><fpage>345</fpage><lpage>353</lpage><?supplied-pmid 29365305?><pub-id pub-id-type="pmid">29365305</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name></person-group><article-title>Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19)</article-title><source>JAMA Cardiol</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1017</pub-id><?supplied-pmid 32293644?><pub-id pub-id-type="pmid">32293644</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name></person-group><article-title>Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China</article-title><source>JAMA Cardiol</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.0950</pub-id><?supplied-pmid 32211816?><pub-id pub-id-type="pmid">32211816</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan</article-title><source>China Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</article-title><source>Intensive Care Med</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00134-020-05991-x</pub-id><?supplied-pmid 32253449?><pub-id pub-id-type="pmid">32253449</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">(2020) Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS) registry protocols. <ext-link ext-link-type="uri" xlink:href="https://leoss.net/">https://leoss.net/</ext-link></mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrales-Medina</surname><given-names>VF</given-names></name><name><surname>Alvarez</surname><given-names>KN</given-names></name><name><surname>Weissfeld</surname><given-names>LA</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Chirinos</surname><given-names>JA</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Newman</surname><given-names>A</given-names></name><name><surname>Loehr</surname><given-names>L</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Elkind</surname><given-names>MS</given-names></name><name><surname>Lyles</surname><given-names>MF</given-names></name><name><surname>Kronmal</surname><given-names>RA</given-names></name><name><surname>Yende</surname><given-names>S</given-names></name></person-group><article-title>Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease</article-title><source>JAMA</source><year>2015</year><volume>313</volume><fpage>264</fpage><lpage>274</lpage><?supplied-pmid 25602997?><pub-id pub-id-type="pmid">25602997</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zilla</surname><given-names>P</given-names></name><name><surname>Bolman</surname><given-names>RM</given-names></name><name><surname>Yacoub</surname><given-names>MH</given-names></name><name><surname>Beyersdorf</surname><given-names>F</given-names></name><name><surname>Sliwa</surname><given-names>K</given-names></name><name><surname>Z&#x000fc;hlke</surname><given-names>L</given-names></name><name><surname>Higgins</surname><given-names>RSD</given-names></name><name><surname>Mayosi</surname><given-names>B</given-names></name><name><surname>Carpentier</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name></person-group><article-title>The Cape Town declaration on access to cardiac surgery in the developing world</article-title><source>J Thorac Cardiovasc Surg</source><year>2018</year><volume>156</volume><fpage>2206</fpage><lpage>2209</lpage><?supplied-pmid 30082076?><pub-id pub-id-type="pmid">30082076</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lwabi</surname><given-names>P</given-names></name><name><surname>Namuyonga</surname><given-names>J</given-names></name><name><surname>Lubega</surname><given-names>S</given-names></name><name><surname>Oketcho</surname><given-names>M</given-names></name><name><surname>Mwambu</surname><given-names>T</given-names></name><name><surname>Sebatta</surname><given-names>E</given-names></name><name><surname>Okello</surname><given-names>E</given-names></name><name><surname>Omagino</surname><given-names>J</given-names></name><name><surname>Sliwa</surname><given-names>K</given-names></name></person-group><article-title>The Uganda Heart Association</article-title><source>Eur Heart J</source><year>2019</year><volume>40</volume><fpage>2396</fpage><lpage>2397</lpage><?supplied-pmid 31539909?><pub-id pub-id-type="pmid">31539909</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sliwa</surname><given-names>K</given-names></name><name><surname>Ntusi</surname><given-names>N</given-names></name></person-group><article-title>Battling cardiovascular diseases in a perfect storm</article-title><source>Circulation</source><year>2019</year><volume>139</volume><fpage>1658</fpage><lpage>1660</lpage><?supplied-pmid 30933612?><pub-id pub-id-type="pmid">30933612</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thienemann</surname><given-names>F</given-names></name><name><surname>Pinto</surname><given-names>F</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Boehm</surname><given-names>M</given-names></name><name><surname>Bazargani</surname><given-names>N</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Sliwa</surname><given-names>K</given-names></name></person-group><article-title>World heart
federation briefing on prevention: coronavirus disease 2019 (COVID-19) in low-income
countries</article-title><source>Glob Heart</source><year>2020</year><volume>15</volume><issue>1</issue><fpage>31</fpage><pub-id pub-id-type="doi">10.5334/gh.778</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Spiering</surname><given-names>W</given-names></name><name><surname>Agabiti Rosei</surname><given-names>E</given-names></name><name><surname>Azizi</surname><given-names>M</given-names></name><name><surname>Burnier</surname><given-names>M</given-names></name><name><surname>Clement</surname><given-names>DL</given-names></name><name><surname>Coca</surname><given-names>A</given-names></name><name><surname>de Simone</surname><given-names>G</given-names></name><name><surname>Dominiczak</surname><given-names>A</given-names></name><name><surname>Kahan</surname><given-names>T</given-names></name><name><surname>Mahfoud</surname><given-names>F</given-names></name><name><surname>Redon</surname><given-names>J</given-names></name><name><surname>Ruilope</surname><given-names>L</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><name><surname>Kerins</surname><given-names>M</given-names></name><name><surname>Kjeldsen</surname><given-names>SE</given-names></name><name><surname>Kreutz</surname><given-names>R</given-names></name><name><surname>Laurent</surname><given-names>S</given-names></name><name><surname>Lip</surname><given-names>GYH</given-names></name><name><surname>McManus</surname><given-names>R</given-names></name><name><surname>Narkiewicz</surname><given-names>K</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><name><surname>Schmieder</surname><given-names>RE</given-names></name><name><surname>Shlyakhto</surname><given-names>E</given-names></name><name><surname>Tsioufis</surname><given-names>C</given-names></name><name><surname>Aboyans</surname><given-names>V</given-names></name><name><surname>Desormais</surname><given-names>I</given-names></name><collab>ESC Scientific Document Group</collab></person-group><article-title>2018 ESC/ESH Guidelines for the management of arterial hypertension</article-title><source>Eur Heart J</source><year>2018</year><volume>39</volume><fpage>3021</fpage><lpage>3104</lpage><?supplied-pmid 30165516?><pub-id pub-id-type="pmid">30165516</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelton</surname><given-names>PK</given-names></name><name><surname>Carey</surname><given-names>RM</given-names></name><name><surname>Aronow</surname><given-names>WS</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Collins</surname><given-names>KJ</given-names></name><name><surname>Dennison Himmelfarb</surname><given-names>C</given-names></name><name><surname>DePalma</surname><given-names>SM</given-names></name><name><surname>Gidding</surname><given-names>S</given-names></name><name><surname>Jamerson</surname><given-names>KA</given-names></name><name><surname>Jones</surname><given-names>DW</given-names></name><name><surname>MacLaughlin</surname><given-names>EJ</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name><name><surname>Ovbiagele</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Spencer</surname><given-names>CC</given-names></name><name><surname>Stafford</surname><given-names>RS</given-names></name><name><surname>Taler</surname><given-names>SJ</given-names></name><name><surname>Thomas</surname><given-names>RJ</given-names></name><name><surname>Williams</surname><given-names>KA</given-names><suffix>Sr</suffix></name><name><surname>Williamson</surname><given-names>JD</given-names></name><name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></name></person-group><article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines</article-title><source>Circulation</source><year>2018</year><volume>138</volume><fpage>e426</fpage><lpage>e483</lpage><?supplied-pmid 30354655?><pub-id pub-id-type="pmid">30354655</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tipnis</surname><given-names>SR</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name><name><surname>Hyde</surname><given-names>R</given-names></name><name><surname>Karran</surname><given-names>E</given-names></name><name><surname>Christie</surname><given-names>G</given-names></name><name><surname>Turner</surname><given-names>AJ</given-names></name></person-group><article-title>A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>33238</fpage><lpage>33243</lpage><?supplied-pmid 10924499?><pub-id pub-id-type="pmid">10924499</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>KM</given-names></name><name><surname>Booz</surname><given-names>GW</given-names></name><name><surname>Dostal</surname><given-names>DE</given-names></name></person-group><article-title>Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system</article-title><source>Annu Rev Physiol</source><year>1992</year><volume>54</volume><fpage>227</fpage><lpage>241</lpage><?supplied-pmid 1562174?><pub-id pub-id-type="pmid">1562174</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaschina</surname><given-names>E</given-names></name><name><surname>Namsolleck</surname><given-names>P</given-names></name><name><surname>Unger</surname><given-names>T</given-names></name></person-group><article-title>AT2 receptors in cardiovascular and renal disease</article-title><source>Pharmacol Res</source><year>2017</year><volume>125</volume><fpage>39</fpage><lpage>47</lpage><?supplied-pmid 28694144?><pub-id pub-id-type="pmid">28694144</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donoghue</surname><given-names>M</given-names></name><name><surname>Hsieh</surname><given-names>F</given-names></name><name><surname>Baronas</surname><given-names>E</given-names></name><name><surname>Godbout</surname><given-names>K</given-names></name><name><surname>Gosselin</surname><given-names>M</given-names></name><name><surname>Stagliano</surname><given-names>N</given-names></name><name><surname>Donovan</surname><given-names>M</given-names></name><name><surname>Woolf</surname><given-names>B</given-names></name><name><surname>Robison</surname><given-names>K</given-names></name><name><surname>Jeyaseelan</surname><given-names>R</given-names></name><name><surname>Breitbart</surname><given-names>RE</given-names></name><name><surname>Acton</surname><given-names>S</given-names></name></person-group><article-title>A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1&#x02013;9</article-title><source>Circ Res</source><year>2000</year><volume>87</volume><fpage>E1</fpage><lpage>9</lpage><?supplied-pmid 10969042?><pub-id pub-id-type="pmid">10969042</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim&#x000f5;es e Silva</surname><given-names>AC</given-names></name><name><surname>Silveira</surname><given-names>KD</given-names></name><name><surname>Ferreira</surname><given-names>AJ</given-names></name><name><surname>Teixeira</surname><given-names>MM</given-names></name></person-group><article-title>ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis</article-title><source>Br J Pharmacol</source><year>2013</year><volume>169</volume><fpage>477</fpage><lpage>492</lpage><?supplied-pmid 23488800?><pub-id pub-id-type="pmid">23488800</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeager</surname><given-names>CL</given-names></name><name><surname>Ashmun</surname><given-names>RA</given-names></name><name><surname>Williams</surname><given-names>RK</given-names></name><name><surname>Cardellichio</surname><given-names>CB</given-names></name><name><surname>Shapiro</surname><given-names>LH</given-names></name><name><surname>Look</surname><given-names>AT</given-names></name><name><surname>Holmes</surname><given-names>KV</given-names></name></person-group><article-title>Human aminopeptidase N is a receptor for human coronavirus 229E</article-title><source>Nature</source><year>1992</year><volume>357</volume><fpage>420</fpage><lpage>422</lpage><?supplied-pmid 1350662?><pub-id pub-id-type="pmid">1350662</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>AJ</given-names></name><name><surname>Hiscox</surname><given-names>JA</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name></person-group><article-title>ACE2: from vasopeptidase to SARS virus receptor</article-title><source>Trends Pharmacol Sci</source><year>2004</year><volume>25</volume><fpage>291</fpage><lpage>294</lpage><?supplied-pmid 15165741?><pub-id pub-id-type="pmid">15165741</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>Structure analysis of the receptor binding of 2019-nCoV</article-title><source>Biochem Biophys Res Commun</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.02.071</pub-id><?supplied-pmid 32451081?><pub-id pub-id-type="pmid">32451081</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>DW</given-names></name><name><surname>Yarski</surname><given-names>M</given-names></name><name><surname>Warner</surname><given-names>FJ</given-names></name><name><surname>Thornhill</surname><given-names>P</given-names></name><name><surname>Parkin</surname><given-names>ET</given-names></name><name><surname>Smith</surname><given-names>AI</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name><name><surname>Turner</surname><given-names>AJ</given-names></name></person-group><article-title>Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>30113</fpage><lpage>30119</lpage><?supplied-pmid 15983030?><pub-id pub-id-type="pmid">15983030</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><?supplied-pmid 32155444?><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>NH</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><?supplied-pmid 32375025?><pub-id pub-id-type="pmid">32375025</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dijkman</surname><given-names>R</given-names></name><name><surname>Jebbink</surname><given-names>MF</given-names></name><name><surname>Deijs</surname><given-names>M</given-names></name><name><surname>Milewska</surname><given-names>A</given-names></name><name><surname>Pyrc</surname><given-names>K</given-names></name><name><surname>Buelow</surname><given-names>E</given-names></name><name><surname>van der Bijl</surname><given-names>A</given-names></name><name><surname>van der Hoek</surname><given-names>L</given-names></name></person-group><article-title>Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63</article-title><source>J Gen Virol</source><year>2012</year><volume>93</volume><fpage>1924</fpage><lpage>1929</lpage><?supplied-pmid 22718567?><pub-id pub-id-type="pmid">22718567</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Huan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chappell</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Leibbrandt</surname><given-names>A</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><fpage>875</fpage><lpage>879</lpage><?supplied-pmid 16007097?><pub-id pub-id-type="pmid">16007097</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>19840</fpage><?supplied-pmid 26813885?><pub-id pub-id-type="pmid">26813885</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ju</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Bai</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>N</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>3594</fpage><?supplied-pmid 24800825?><pub-id pub-id-type="pmid">24800825</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>H</given-names></name></person-group><article-title>Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease</article-title><source>Shock</source><year>2016</year><volume>46</volume><fpage>239</fpage><lpage>248</lpage><?supplied-pmid 27082314?><pub-id pub-id-type="pmid">27082314</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Huan</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Sarao</surname><given-names>R</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Leong-Poi</surname><given-names>H</given-names></name><name><surname>Crackower</surname><given-names>MA</given-names></name><name><surname>Fukamizu</surname><given-names>A</given-names></name><name><surname>Hui</surname><given-names>CC</given-names></name><name><surname>Hein</surname><given-names>L</given-names></name><name><surname>Uhlig</surname><given-names>S</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 protects from severe acute lung failure</article-title><source>Nature</source><year>2005</year><volume>436</volume><fpage>112</fpage><lpage>116</lpage><?supplied-pmid 16001071?><pub-id pub-id-type="pmid">16001071</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Benthin</surname><given-names>C</given-names></name><name><surname>Zeno</surname><given-names>B</given-names></name><name><surname>Albertson</surname><given-names>TE</given-names></name><name><surname>Boyd</surname><given-names>J</given-names></name><name><surname>Christie</surname><given-names>JD</given-names></name><name><surname>Hall</surname><given-names>R</given-names></name><name><surname>Poirier</surname><given-names>G</given-names></name><name><surname>Ronco</surname><given-names>JJ</given-names></name><name><surname>Tidswell</surname><given-names>M</given-names></name><name><surname>Hardes</surname><given-names>K</given-names></name><name><surname>Powley</surname><given-names>WM</given-names></name><name><surname>Wright</surname><given-names>TJ</given-names></name><name><surname>Siederer</surname><given-names>SK</given-names></name><name><surname>Fairman</surname><given-names>DA</given-names></name><name><surname>Lipson</surname><given-names>DA</given-names></name><name><surname>Bayliffe</surname><given-names>AI</given-names></name><name><surname>Lazaar</surname><given-names>AL</given-names></name></person-group><article-title>A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome</article-title><source>Crit Care</source><year>2017</year><volume>21</volume><fpage>234</fpage><?supplied-pmid 28877748?><pub-id pub-id-type="pmid">28877748</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><name><surname>van Goor</surname><given-names>H</given-names></name><name><surname>Turner</surname><given-names>AJ</given-names></name><name><surname>Rushworth</surname><given-names>CA</given-names></name><name><surname>Michaud</surname><given-names>AA</given-names></name><name><surname>Corvol</surname><given-names>P</given-names></name><name><surname>Navis</surname><given-names>G</given-names></name></person-group><article-title>Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats</article-title><source>Exp Physiol</source><year>2008</year><volume>93</volume><fpage>631</fpage><lpage>638</lpage><?supplied-pmid 18192334?><pub-id pub-id-type="pmid">18192334</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocaranza</surname><given-names>MP</given-names></name><name><surname>Godoy</surname><given-names>I</given-names></name><name><surname>Jalil</surname><given-names>JE</given-names></name><name><surname>Varas</surname><given-names>M</given-names></name><name><surname>Collantes</surname><given-names>P</given-names></name><name><surname>Pinto</surname><given-names>M</given-names></name><name><surname>Roman</surname><given-names>M</given-names></name><name><surname>Ramirez</surname><given-names>C</given-names></name><name><surname>Copaja</surname><given-names>M</given-names></name><name><surname>Diaz-Araya</surname><given-names>G</given-names></name><name><surname>Castro</surname><given-names>P</given-names></name><name><surname>Lavandero</surname><given-names>S</given-names></name></person-group><article-title>Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat</article-title><source>Hypertension</source><year>2006</year><volume>48</volume><fpage>572</fpage><lpage>578</lpage><?supplied-pmid 16908757?><pub-id pub-id-type="pmid">16908757</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrario</surname><given-names>CM</given-names></name><name><surname>Jessup</surname><given-names>J</given-names></name><name><surname>Chappell</surname><given-names>MC</given-names></name><name><surname>Averill</surname><given-names>DB</given-names></name><name><surname>Brosnihan</surname><given-names>KB</given-names></name><name><surname>Tallant</surname><given-names>EA</given-names></name><name><surname>Diz</surname><given-names>DI</given-names></name><name><surname>Gallagher</surname><given-names>PE</given-names></name></person-group><article-title>Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>2605</fpage><lpage>2610</lpage><?supplied-pmid 15897343?><pub-id pub-id-type="pmid">15897343</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epelman</surname><given-names>S</given-names></name><name><surname>Shrestha</surname><given-names>K</given-names></name><name><surname>Troughton</surname><given-names>RW</given-names></name><name><surname>Francis</surname><given-names>GS</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>AL</given-names></name><name><surname>Tang</surname><given-names>WH</given-names></name></person-group><article-title>Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes</article-title><source>J Card Fail</source><year>2009</year><volume>15</volume><fpage>565</fpage><lpage>571</lpage><?supplied-pmid 19700132?><pub-id pub-id-type="pmid">19700132</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>TE</given-names></name><name><surname>Kalman</surname><given-names>JM</given-names></name><name><surname>Patel</surname><given-names>SK</given-names></name><name><surname>Mearns</surname><given-names>M</given-names></name><name><surname>Velkoska</surname><given-names>E</given-names></name><name><surname>Burrell</surname><given-names>LM</given-names></name></person-group><article-title>Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling</article-title><source>Europace</source><year>2017</year><volume>19</volume><fpage>1280</fpage><lpage>1287</lpage><?supplied-pmid 27738071?><pub-id pub-id-type="pmid">27738071</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemnes</surname><given-names>AR</given-names></name><name><surname>Rathinasabapathy</surname><given-names>A</given-names></name><name><surname>Austin</surname><given-names>EA</given-names></name><name><surname>Brittain</surname><given-names>EL</given-names></name><name><surname>Carrier</surname><given-names>EJ</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Fessel</surname><given-names>JP</given-names></name><name><surname>Fike</surname><given-names>CD</given-names></name><name><surname>Fong</surname><given-names>P</given-names></name><name><surname>Fortune</surname><given-names>N</given-names></name><name><surname>Gerszten</surname><given-names>RE</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Kaplowitz</surname><given-names>M</given-names></name><name><surname>Newman</surname><given-names>JH</given-names></name><name><surname>Piana</surname><given-names>R</given-names></name><name><surname>Pugh</surname><given-names>ME</given-names></name><name><surname>Rice</surname><given-names>TW</given-names></name><name><surname>Robbins</surname><given-names>IM</given-names></name><name><surname>Wheeler</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Loyd</surname><given-names>JE</given-names></name><name><surname>West</surname><given-names>J</given-names></name></person-group><article-title>A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension</article-title><source>Eur Respir J</source><year>2018</year><pub-id pub-id-type="doi">10.1183/13993003.02638-2017</pub-id><?supplied-pmid 29903860?><pub-id pub-id-type="pmid">29903860</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZJ</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>ZG</given-names></name><name><surname>Yang</surname><given-names>WY</given-names></name><collab>China National Diabetes and Metabolic Disorders Study Group</collab></person-group><article-title>Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007&#x02013;2008 China National Diabetes and Metabolic Disorders Study</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><fpage>213</fpage><lpage>220</lpage><?supplied-pmid 21719451?><pub-id pub-id-type="pmid">21719451</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Xiang</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id><?supplied-pmid 32315061?><pub-id pub-id-type="pmid">32315061</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Bai</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name></person-group><article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China</article-title><source>JAMA Intern Med</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id><?supplied-pmid 32338717?><pub-id pub-id-type="pmid">32338717</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasselli</surname><given-names>G</given-names></name><name><surname>Zangrillo</surname><given-names>A</given-names></name><name><surname>Zanella</surname><given-names>A</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Cabrini</surname><given-names>L</given-names></name><name><surname>Castelli</surname><given-names>A</given-names></name><name><surname>Cereda</surname><given-names>D</given-names></name><name><surname>Coluccello</surname><given-names>A</given-names></name><name><surname>Foti</surname><given-names>G</given-names></name><name><surname>Fumagalli</surname><given-names>R</given-names></name><name><surname>Iotti</surname><given-names>G</given-names></name><name><surname>Latronico</surname><given-names>N</given-names></name><name><surname>Lorini</surname><given-names>L</given-names></name><name><surname>Merler</surname><given-names>S</given-names></name><name><surname>Natalini</surname><given-names>G</given-names></name><name><surname>Piatti</surname><given-names>A</given-names></name><name><surname>Ranieri</surname><given-names>MV</given-names></name><name><surname>Scandroglio</surname><given-names>AM</given-names></name><name><surname>Storti</surname><given-names>E</given-names></name><name><surname>Cecconi</surname><given-names>M</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><collab>COVID-19 Lombardy ICU Network</collab></person-group><article-title>Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.5394</pub-id><?supplied-pmid 32250385?><pub-id pub-id-type="pmid">32250385</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hao</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Shao</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Weintraub</surname><given-names>WS</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><collab>China Hypertension Survey Investigators</collab></person-group><article-title>Status of hypertension in China: Results from the China hypertension survey, 2012&#x02013;2015</article-title><source>Circulation</source><year>2018</year><volume>137</volume><fpage>2344</fpage><lpage>2356</lpage><?supplied-pmid 29449338?><pub-id pub-id-type="pmid">29449338</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>LS</given-names></name><collab>Writing Group of 2010 Chinese Guidelines for the Management of Hypertension</collab></person-group><article-title>2010 Chinese guidelines for the management of hypertension</article-title><source>Zhonghua Xin Xue Guan Bing Za Zhi</source><year>2011</year><volume>39</volume><fpage>579</fpage><lpage>615</lpage><?supplied-pmid 22088239?><pub-id pub-id-type="pmid">22088239</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Schwabe</surname><given-names>Ulrich</given-names></name><name><surname>Paffrath</surname><given-names>Dieter</given-names></name><name><surname>Ludwig</surname><given-names>Wolf-Dieter</given-names></name><name><surname>Klauber</surname><given-names>J&#x000fc;rgen</given-names></name></person-group><source>Arzneiverordnungs-Report 2019</source><year>2019</year><publisher-loc>Berlin, Heidelberg</publisher-loc><publisher-name>Springer Berlin Heidelberg</publisher-name></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Linderman</surname><given-names>GC</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Mu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Spatz</surname><given-names>ES</given-names></name><name><surname>Spertus</surname><given-names>JA</given-names></name><name><surname>Masoudi</surname><given-names>FA</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name></person-group><article-title>Prevalence, awareness, treatment, and control of hypertension in China: data from 1&#x000b7;7 million adults in a population-based screening study (China PEACE Million Persons Project)</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>2549</fpage><lpage>2558</lpage><?supplied-pmid 29102084?><pub-id pub-id-type="pmid">29102084</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuster</surname><given-names>GM</given-names></name><name><surname>Pfister</surname><given-names>O</given-names></name><name><surname>Burkard</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Twerenbold</surname><given-names>R</given-names></name><name><surname>Haaf</surname><given-names>P</given-names></name><name><surname>Widmer</surname><given-names>AF</given-names></name><name><surname>Osswald</surname><given-names>S</given-names></name></person-group><article-title>SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?</article-title><source>Eur Heart J</source><year>2020</year><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa235</pub-id><?supplied-pmid 32432723?><pub-id pub-id-type="pmid">32432723</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bavishi</surname><given-names>C</given-names></name><name><surname>Maddox</surname><given-names>TM</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name></person-group><article-title>Coronavirus Disease 2019 (COVID-19) infection and renin angiotensin system blockers</article-title><source>JAMA Cardiol</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1282</pub-id><?supplied-pmid 32242890?><pub-id pub-id-type="pmid">32242890</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>AB</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name></person-group><article-title>COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.4812</pub-id><?supplied-pmid 32432681?><pub-id pub-id-type="pmid">32432681</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Karakiulakis</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title><source>Lancet Respir Med</source><year>2020</year><volume>8</volume><fpage>e21</fpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30116-8</pub-id><?supplied-pmid 32171062?><pub-id pub-id-type="pmid">32171062</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommerstein</surname><given-names>R</given-names></name><name><surname>Gr&#x000e4;ni</surname><given-names>C</given-names></name></person-group><article-title>Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19</article-title><source>BMJ</source><year>2020</year><volume>368</volume><fpage>m810</fpage><pub-id pub-id-type="pmid">32111649</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>JH</given-names></name></person-group><article-title>Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19</article-title><source>Travel Med</source><year>2020</year><pub-id pub-id-type="doi">10.1093/jtm/taaa041</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esler</surname><given-names>M</given-names></name><name><surname>Esler</surname><given-names>D</given-names></name></person-group><article-title>Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?</article-title><source>J Hypertens</source><year>2020</year><volume>38</volume><fpage>781</fpage><lpage>782</lpage><?supplied-pmid 32195824?><pub-id pub-id-type="pmid">32195824</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>TY</given-names></name><name><surname>Redwood</surname><given-names>S</given-names></name><name><surname>Prendergast</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name></person-group><article-title>Coronaviruses and the cardiovascular system: acute and long-term implications</article-title><source>Eur Heart J</source><year>2020</year><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa231</pub-id><?supplied-pmid 32186331?><pub-id pub-id-type="pmid">32186331</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><etal/></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><?supplied-pmid 32007143?><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Fourth universal definition of myocardial infarction (2018)</article-title><source>Eur Heart J</source><year>2019</year><volume>40</volume><fpage>237</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehy462</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>M</given-names></name><name><surname>Biener</surname><given-names>M</given-names></name><name><surname>Vafaie</surname><given-names>M</given-names></name><etal/></person-group><article-title>Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome</article-title><source>Clin Chem</source><year>2012</year><volume>58</volume><issue>1</issue><fpage>209</fpage><lpage>218</lpage><?supplied-pmid 22134520?><pub-id pub-id-type="pmid">22134520</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannitsis</surname><given-names>E</given-names></name><name><surname>Katus</surname><given-names>HA</given-names></name></person-group><article-title>Cardiac troponin level elevations not related to acute coronary syndromes</article-title><source>Nat Rev Cardiol</source><year>2013</year><volume>10</volume><issue>11</issue><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2013.129</pub-id><?supplied-pmid 23979214?><pub-id pub-id-type="pmid">23979214</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFalls</surname><given-names>EO</given-names></name><name><surname>Larsen</surname><given-names>G</given-names></name><name><surname>Johnson</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Outcomes of hospitalized patients with non-acute coronary syndrome and elevated cardiac troponin level</article-title><source>Am J Med</source><year>2011</year><volume>124</volume><issue>7</issue><fpage>630</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2011.02.024</pub-id><?supplied-pmid 21601821?><pub-id pub-id-type="pmid">21601821</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iversen</surname><given-names>K</given-names></name><name><surname>K&#x000f8;ber</surname><given-names>L</given-names></name><name><surname>G&#x000f8;tze</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Troponin T is a strong marker of mortality in hospitalized patients</article-title><source>Int J Cardiol</source><year>2013</year><volume>168</volume><issue>2</issue><fpage>818</fpage><lpage>824</lpage><?supplied-pmid 23117016?><pub-id pub-id-type="pmid">23117016</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>JC</given-names></name><name><surname>Schwartz</surname><given-names>KL</given-names></name><name><surname>Campitelli</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Acute myocardial infarction after laboratory-confirmed influenza infection</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><issue>4</issue><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1702090</pub-id><?supplied-pmid 29365305?><pub-id pub-id-type="pmid">29365305</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inciardi</surname><given-names>RM</given-names></name><name><surname>Lupi</surname><given-names>L</given-names></name><name><surname>Zaccone</surname><given-names>G</given-names></name><name><surname>Italia</surname><given-names>L</given-names></name><name><surname>Raffo</surname><given-names>M</given-names></name><name><surname>Tomasoni</surname><given-names>D</given-names></name><name><surname>Cani</surname><given-names>DS</given-names></name><name><surname>Cerini</surname><given-names>M</given-names></name><name><surname>Farina</surname><given-names>D</given-names></name><name><surname>Gavazzi</surname><given-names>E</given-names></name><name><surname>Maroldi</surname><given-names>R</given-names></name><name><surname>Adamo</surname><given-names>M</given-names></name><name><surname>Ammirati</surname><given-names>E</given-names></name><name><surname>Sinagra</surname><given-names>G</given-names></name><name><surname>Lombardi</surname><given-names>CM</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name></person-group><article-title>Cardiac involvement in a patient with Coronavirus Disease 2019 (COVID-19)</article-title><source>JAMA Cardiol</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1096</pub-id><?supplied-pmid 32219357?><pub-id pub-id-type="pmid">32219357</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>SS</given-names></name><name><surname>Cheng</surname><given-names>CW</given-names></name><name><surname>Fu</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study</article-title><source>Circulation</source><year>2003</year><volume>108</volume><issue>15</issue><fpage>1798</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000094737.21775.32</pub-id><?supplied-pmid 14504188?><pub-id pub-id-type="pmid">14504188</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>ZV</given-names></name><name><surname>Ferdinandy</surname><given-names>P</given-names></name><name><surname>Liaudet</surname><given-names>L</given-names></name><name><surname>Pacher</surname><given-names>P</given-names></name></person-group><article-title>Drug-induced mitochondrial dysfunction and cardiotoxicity</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2015</year><volume>309</volume><issue>9</issue><fpage>H1453</fpage><lpage>H1467</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00554.2015</pub-id><?supplied-pmid 26386112?><pub-id pub-id-type="pmid">26386112</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>J</given-names></name><name><surname>Hettwer</surname><given-names>S</given-names></name><name><surname>Schuermann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Elevated troponin in septic patients in the emergency department: frequency, causes, and prognostic implications</article-title><source>Clin Res Cardiol</source><year>2014</year><volume>103</volume><issue>7</issue><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1007/s00392-014-0684-4</pub-id><?supplied-pmid 24535379?><pub-id pub-id-type="pmid">24535379</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasile</surname><given-names>VC</given-names></name><name><surname>Chai</surname><given-names>HS</given-names></name><name><surname>Abdeldayem</surname><given-names>D</given-names></name><name><surname>Afessa</surname><given-names>B</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name></person-group><article-title>Elevated cardiac troponin T levels in critically ill patients with sepsis</article-title><source>Am J Med</source><year>2013</year><volume>126</volume><issue>12</issue><fpage>1114</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2013.06.029</pub-id><?supplied-pmid 24083646?><pub-id pub-id-type="pmid">24083646</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landesberg</surname><given-names>G</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><name><surname>Gilon</surname><given-names>D</given-names></name><etal/></person-group><article-title>Troponin elevation in severe sepsis and septic shock: the role of left ventricular diastolic dysfunction and right ventricular dilatation*</article-title><source>Crit Care Med</source><year>2014</year><volume>42</volume><issue>4</issue><fpage>790</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000000107</pub-id><?supplied-pmid 24365861?><pub-id pub-id-type="pmid">24365861</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turer</surname><given-names>AT</given-names></name><name><surname>Addo</surname><given-names>TA</given-names></name><name><surname>Martin</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><issue>24</issue><fpage>2398</fpage><lpage>2405</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.11.066</pub-id><?supplied-pmid 21658559?><pub-id pub-id-type="pmid">21658559</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siriwardena</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>V</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Pemberton</surname><given-names>CJ</given-names></name></person-group><article-title>Cardiac biomarker responses to dobutamine stress echocardiography in healthy volunteers and patients with coronary artery disease</article-title><source>Clin Chem</source><year>2012</year><volume>58</volume><issue>10</issue><fpage>1492</fpage><lpage>1494</lpage><?supplied-pmid 22896711?><pub-id pub-id-type="pmid">22896711</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>A</given-names></name><name><surname>Bergna</surname><given-names>A</given-names></name><name><surname>Acciarri</surname><given-names>C</given-names></name><name><surname>Galli</surname><given-names>M</given-names></name><name><surname>Zehender</surname><given-names>G</given-names></name></person-group><article-title>Early phylogenetic estimate of the effective reproduction number of SARS-CoV-2</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25723</pub-id><?supplied-pmid 32427358?><pub-id pub-id-type="pmid">32427358</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Hou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Correlation of chest CT and RT-PCR testing in Coronavirus Disease 2019 (COVID-19) in China: a report of 1014 cases</article-title><source>Radiology</source><year>2020</year><pub-id pub-id-type="doi">10.1148/radiol.2020200642</pub-id><?supplied-pmid 32101510?><pub-id pub-id-type="pmid">32101510</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name></person-group><article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title><source>J Thromb Haemost</source><year>2020</year><volume>18</volume><issue>4</issue><fpage>844</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1111/jth.14768</pub-id><?supplied-pmid 32073213?><pub-id pub-id-type="pmid">32073213</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://www.acc.org/latest-incardiology/articles-/2020/03/18/15/25/troponin-and-bnp-use-in-covid19">https://www.acc.org/latest-incardiology/articles-/2020/03/18/15/25/troponin-and-bnp-use-in-covid19</ext-link></mixed-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roffi</surname><given-names>M</given-names></name><name><surname>Patrono</surname><given-names>C</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><etal/></person-group><article-title>2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><issue>3</issue><fpage>267</fpage><lpage>315</lpage><?supplied-pmid 26320110?><pub-id pub-id-type="pmid">26320110</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoyanov</surname><given-names>KM</given-names></name><name><surname>Hund</surname><given-names>H</given-names></name><name><surname>Biener</surname><given-names>M</given-names></name><etal/></person-group><article-title>RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction</article-title><source>Eur Heart J Acute Cardiovasc Care</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>39</fpage><lpage>51</lpage><?supplied-pmid 31298551?><pub-id pub-id-type="pmid">31298551</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twerenbold</surname><given-names>R</given-names></name><name><surname>Costabel</surname><given-names>JP</given-names></name><name><surname>Nestelberger</surname><given-names>T</given-names></name><etal/></person-group><article-title>Outcome of applying the ESC 0/1-hour algorithm in patients with suspected myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2019</year><volume>74</volume><issue>4</issue><fpage>483</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.05.046</pub-id><?supplied-pmid 31345421?><pub-id pub-id-type="pmid">31345421</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>B</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name><name><surname>James</surname><given-names>S</given-names></name></person-group><article-title>The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes</article-title><source>Am Heart J</source><year>2010</year><volume>160</volume><issue>2</issue><fpage>224</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2010.05.023</pub-id><?supplied-pmid 20691825?><pub-id pub-id-type="pmid">20691825</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobs</surname><given-names>A</given-names></name><name><surname>Mehta</surname><given-names>SR</given-names></name><name><surname>Montalescot</surname><given-names>G</given-names></name><etal/></person-group><article-title>Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials</article-title><source>Lancet</source><year>2017</year><volume>390</volume><issue>10096</issue><fpage>737</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31490-3</pub-id><?supplied-pmid 28778541?><pub-id pub-id-type="pmid">28778541</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><mixed-citation publication-type="other">(2020) ACC Clinical Bulletin: COVID 19 Clinical Guidance For the CV Care Team. <ext-link ext-link-type="uri" xlink:href="https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/2020/02/S20028-ACC-Clinical-Bulletin-Coronavirus.pdf">https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/2020/02/S20028-ACC-Clinical-Bulletin-Coronavirus.pdf</ext-link>. Accessed 13 April 2020</mixed-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driggin</surname><given-names>E</given-names></name><name><surname>Madhavan</surname><given-names>MV</given-names></name><name><surname>Bikdeli</surname><given-names>B</given-names></name><name><surname>Chuich</surname><given-names>T</given-names></name><name><surname>Laracy</surname><given-names>J</given-names></name><name><surname>Bondi-Zoccai</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>TS</given-names></name><name><surname>Nigoghossian</surname><given-names>C</given-names></name><name><surname>Zidar</surname><given-names>DA</given-names></name><name><surname>Haythe</surname><given-names>J</given-names></name><name><surname>Brodie</surname><given-names>D</given-names></name><name><surname>Beckman</surname><given-names>JA</given-names></name><name><surname>Kirtane</surname><given-names>AJ</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Parikh</surname><given-names>SA</given-names></name></person-group><article-title>Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic</article-title><source>J Am Coll Cardiol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jacc.2020.03.031</pub-id><?supplied-pmid 32311448?><pub-id pub-id-type="pmid">32311448</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://dgk.org/daten/echo-anleitung-in-zeiten-von-covid-19_final-1.pdf">https://dgk.org/daten/echo-anleitung-in-zeiten-von-covid-19_final-1.pdf</ext-link></mixed-citation></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">American College of Cardiology (2020) COVID-19 Clinical Guidance For the Cardiovascular Care Team. <ext-link ext-link-type="uri" xlink:href="https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/2020/02/S20028-ACC-Clinical-Bulletin-Coronavirus.pdf">https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/2020/02/S20028-ACC-Clinical-Bulletin-Coronavirus.pdf</ext-link>. Accessed 15 May 2020</mixed-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alon</surname><given-names>D</given-names></name><name><surname>Stein</surname><given-names>GY</given-names></name><name><surname>Korenfeld</surname><given-names>R</given-names></name><name><surname>Fuchs</surname><given-names>S</given-names></name></person-group><article-title>Predictors and outcomes of infection-related hospital admissions of heart failure patients</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e72476</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0072476</pub-id><?supplied-pmid 24009684?><pub-id pub-id-type="pmid">24009684</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoval</surname><given-names>C</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name><name><surname>Krueger</surname><given-names>P</given-names></name><name><surname>Smieja</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Loeb</surname><given-names>MB</given-names></name></person-group><article-title>Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure</article-title><source>Epidemiol Infect</source><year>2007</year><volume>135</volume><fpage>574</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1017/S095026880600714X</pub-id><?supplied-pmid 16938140?><pub-id pub-id-type="pmid">16938140</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyt&#x000f6;maa</surname><given-names>S</given-names></name><name><surname>Hegde</surname><given-names>S</given-names></name><name><surname>Claggett</surname><given-names>B</given-names></name><name><surname>Udell</surname><given-names>JA</given-names></name><name><surname>Rosamond</surname><given-names>W</given-names></name><name><surname>Temte</surname><given-names>J</given-names></name><name><surname>Nichol</surname><given-names>K</given-names></name><name><surname>Wright</surname><given-names>JD</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Vardeny</surname><given-names>O</given-names></name></person-group><article-title>Association of influenza-like illness activity with hospitalizations for heart failure: the atherosclerosis risk in communities study</article-title><source>JAMA Cardiol</source><year>2019</year><volume>4</volume><issue>4</issue><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2019.0549</pub-id><?supplied-pmid 30916717?><pub-id pub-id-type="pmid">30916717</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modin</surname><given-names>D</given-names></name><name><surname>Jorgensen</surname><given-names>ME</given-names></name><name><surname>Gislason</surname><given-names>G</given-names></name><name><surname>Jensen</surname><given-names>JS</given-names></name><name><surname>Kober</surname><given-names>L</given-names></name><name><surname>Claggett</surname><given-names>B</given-names></name><name><surname>Hegde</surname><given-names>SM</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Torp-Pedersen</surname><given-names>C</given-names></name><name><surname>Biering-S&#x000f8;rensen</surname><given-names>T</given-names></name></person-group><article-title>Influenza vaccine in heart failure: cumulative number of vaccinations, frequency, timing, and survival: a Danish Nationwide Cohort Study</article-title><source>Circulation</source><year>2019</year><volume>139</volume><fpage>575</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.036788</pub-id><?supplied-pmid 30586760?><pub-id pub-id-type="pmid">30586760</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JW</given-names></name><name><surname>Ng</surname><given-names>CK</given-names></name><name><surname>Chan</surname><given-names>YH</given-names></name><name><surname>Mok</surname><given-names>TY</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>SY</given-names></name><name><surname>Law</surname><given-names>WL</given-names></name><name><surname>Lee</surname><given-names>MP</given-names></name><name><surname>Li</surname><given-names>PC</given-names></name></person-group><article-title>Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)</article-title><source>Thorax</source><year>2003</year><volume>58</volume><issue>8</issue><fpage>686</fpage><lpage>689</lpage><?supplied-pmid 12885985?><pub-id pub-id-type="pmid">12885985</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Zhi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Bi</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China</article-title><source>Clin Res Cardiol</source><year>2020</year><volume>109</volume><fpage>531</fpage><lpage>538</lpage><?supplied-pmid 32161990?><pub-id pub-id-type="pmid">32161990</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Hao</surname><given-names>G</given-names></name></person-group><article-title>The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease</article-title><source>Cardiovasc Res</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cvr/cvaa093</pub-id><?supplied-pmid 32267921?><pub-id pub-id-type="pmid">32267921</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala</surname><given-names>S</given-names></name><name><surname>Peretto</surname><given-names>G</given-names></name><name><surname>Gramegna</surname><given-names>M</given-names></name><name><surname>Palmisano</surname><given-names>A</given-names></name><name><surname>Villatore</surname><given-names>A</given-names></name><name><surname>Vignale</surname><given-names>D</given-names></name><name><surname>De Cobelli</surname><given-names>F</given-names></name><name><surname>Tresoldi</surname><given-names>M</given-names></name><name><surname>Cappelletti</surname><given-names>AM</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Godino</surname><given-names>C</given-names></name><name><surname>Esposito</surname><given-names>A</given-names></name></person-group><article-title>Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection</article-title><source>Eur Heart J</source><year>2020</year><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa286</pub-id><?supplied-pmid 32363406?><pub-id pub-id-type="pmid">32363406</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>XH</given-names></name><name><surname>Li</surname><given-names>TY</given-names></name><name><surname>He</surname><given-names>ZC</given-names></name><etal/></person-group><article-title>A pathological report of three covid-19 cases by minimally invasive autopsies</article-title><source>Zhonghua Bing Li Xue Za Zhi</source><year>2020</year><volume>49</volume><fpage>E009</fpage></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karakike</surname><given-names>E</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name></person-group><article-title>Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis</article-title><source>Front Immunol</source><year>2019</year><volume>31</volume><issue>10</issue><fpage>55</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00055</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Tattersall</surname><given-names>RS</given-names></name><name><surname>Manson</surname><given-names>JJ</given-names></name><collab>HLH Across Speciality Collaboration, UK</collab></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10229</issue><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id><?supplied-pmid 32192578?><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathan</surname><given-names>N</given-names></name><name><surname>Hemingway</surname><given-names>CA</given-names></name><name><surname>Alizadeh</surname><given-names>AA</given-names></name><name><surname>Stephens</surname><given-names>AC</given-names></name><name><surname>Boldrick</surname><given-names>JC</given-names></name><name><surname>Oragui</surname><given-names>EE</given-names></name><name><surname>McCabe</surname><given-names>C</given-names></name><name><surname>Welch</surname><given-names>SB</given-names></name><name><surname>Whitney</surname><given-names>A</given-names></name><name><surname>O'Gara</surname><given-names>P</given-names></name><name><surname>Nadel</surname><given-names>S</given-names></name><name><surname>Relman</surname><given-names>DA</given-names></name><name><surname>Harding</surname><given-names>SE</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name></person-group><article-title>Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock</article-title><source>Lancet</source><year>2004</year><volume>363</volume><issue>9404</issue><fpage>203</fpage><lpage>209</lpage><?supplied-pmid 14738793?><pub-id pub-id-type="pmid">14738793</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madjid</surname><given-names>M</given-names></name><name><surname>Safavi-Naeini</surname><given-names>P</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Vardeny</surname><given-names>O</given-names></name></person-group><article-title>Potential effects of coronaviruses on the cardiovascular system: a review</article-title><source>JAMA Cardiol</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1286</pub-id><?supplied-pmid 32219363?><pub-id pub-id-type="pmid">32219363</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shakoory</surname><given-names>B</given-names></name><name><surname>Carcillo</surname><given-names>JA</given-names></name><name><surname>Chatham</surname><given-names>WW</given-names></name><name><surname>Amdur</surname><given-names>RL</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Cron</surname><given-names>RQ</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name></person-group><article-title>Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial</article-title><source>Crit Care Med</source><year>2016</year><volume>44</volume><issue>2</issue><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000001402</pub-id><?supplied-pmid 26584195?><pub-id pub-id-type="pmid">26584195</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>A</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name></person-group><article-title>Effective treatment of severe COVID-19 patients with tocilizumab</article-title><source>PNAS</source><year>2020</year><pub-id pub-id-type="doi">10.1073/pnas.2005615117</pub-id><?supplied-pmid 32434921?><pub-id pub-id-type="pmid">32434921</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favalli</surname><given-names>EG</given-names></name><name><surname>Biggioggero</surname><given-names>M</given-names></name><name><surname>Maioli</surname><given-names>G</given-names></name><name><surname>Caporali</surname><given-names>R</given-names></name></person-group><article-title>Baricitinib for COVID-19: a suitable treatment?</article-title><source>Lancet Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30262-0</pub-id><?supplied-pmid 32251638?><pub-id pub-id-type="pmid">32251638</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><mixed-citation publication-type="other">(2020) Losartan for patients with COVID-19 requiring hospitalization. ClinicalTrials.gov Identifier: NCT04312009.</mixed-citation></ref></ref-list></back></article>